Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Revolution Medicines (RVMD) Accounts Payables (2019 - 2025)

Revolution Medicines has reported Accounts Payables over the past 7 years, most recently at $64.6 million for Q4 2025.

  • Quarterly results put Accounts Payables at $64.6 million for Q4 2025, up 18.72% from a year ago — trailing twelve months through Dec 2025 was $64.6 million (up 18.72% YoY), and the annual figure for FY2025 was $64.6 million, up 18.72%.
  • Accounts Payables for Q4 2025 was $64.6 million at Revolution Medicines, down from $74.8 million in the prior quarter.
  • Over the last five years, Accounts Payables for RVMD hit a ceiling of $74.8 million in Q3 2025 and a floor of $9.6 million in Q1 2021.
  • Median Accounts Payables over the past 5 years was $26.9 million (2024), compared with a mean of $32.2 million.
  • Biggest five-year swings in Accounts Payables: decreased 17.45% in 2024 and later skyrocketed 206.06% in 2025.
  • Revolution Medicines' Accounts Payables stood at $14.1 million in 2021, then soared by 51.57% to $21.3 million in 2022, then soared by 190.0% to $61.8 million in 2023, then decreased by 11.91% to $54.4 million in 2024, then increased by 18.72% to $64.6 million in 2025.
  • The last three reported values for Accounts Payables were $64.6 million (Q4 2025), $74.8 million (Q3 2025), and $56.8 million (Q2 2025) per Business Quant data.